103233-24-5

Upstream product

• 32780-06-6 (5S)-5-(hydroxymethyl)-2-oxo-tetrahydrofuran 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 114142-19-7 S-γ-tert-butyldiphenylsilyloxymethyl-γ-butyrolactone 
• 74-88-4 methyl iodide 
• 21461-84-7 (2S)-tetrahydro-5-oxofuran-2-carboxylic acid 
• 130606-67-6 C₁₁H₁₈O₄ 
• 102717-29-3 (5S)-5-({[tert-butyl(diphenyl)silyl]oxy}methyl)dihydrofuran-2(3H)-one 
• 56-86-0 L-glutamic acid 

Downstream Products

• 109000-29-5 (3R,5S)-dimethyl-<6-<(tert-butyldiphenylsilyl)oxy>-3-methyl-2-oxo-5-(trimethylsiloxy)hexyl>phosphonate 
• 1519887-63-8 C₃₀H₄₀O₄Si 
• 1519887-49-0 (2S,3R,5S)-5-[(tert-butyldiphenylsilyl)oxymethyl]-3-methyl-2-(phenylthiomethyl)tetrahydrofuran 
• 1519887-51-4 C₂₉H₃₆O₃SSi 
• 1519887-54-7 (2R,3R,5S)-5-[(tert-butyldiphenylsilyl)oxymethyl]-3-methyltetrahydrofuran-2-carbaldehyde 
• 1519887-56-9 C₂₃H₂₉O₄Si^(1-)*K⁽¹⁺⁾ 
• 1519887-58-1 (R)-3-methylcyclohex-2-en-1-yl (2R,3R,5S)-5-[(tert-butyldiphenylsilyl)oxymethyl]-3-methyltetrahydrofuran-2-carboxylate 
• 1519887-61-6 C₃₀H₄₀O₄Si 
• 1519887-70-7 (1R,3S,5R,3a'S,4'S,7a'S)-3-[(tert-butyldiphenylsilyl)-oxymethyl ]4'-iodo-5,7a'-dimethyl-2,3'-dioxaspiro[cyclopentane-1,1'-hexahydroindan]-2'-one 
• 1519887-72-9 (1S,3S,5R,3a'S,4'S,7a'S)-3-[(tert-butyldiphenylsilyl)-oxymethyl ]4'-iodo-5,7a'-dimethyl-2,3'-dioxaspiro[cyclopentane-1,1'-hexahydroindan]-2'-one 
• 1417797-17-1 (3R,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-3-fluoro-3-methyldihydrofuran-2(3H)-one 
• 123827-81-6 (2R,4S,5R)-1-(tert-Butyl-diphenyl-silanyloxy)-4-methyl-hexane-2,5-diol 
• 123827-81-6 (2R,4S,5S)-1-(tert-Butyl-diphenyl-silanyloxy)-4-methyl-hexane-2,5-diol 
• 123827-81-6 (2R,4R,5R)-1-(tert-Butyl-diphenyl-silanyloxy)-4-methyl-hexane-2,5-diol 

Relevant academic research and scientific papers

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTICS COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to halogenated nucleosides optionally conjugated to a phosphorus oxide or pharmaceutically acceptable salts thereof. In certain embodiments, the disclosure relates to conjugate compounds or pharmaceutically acceptable salts thereof comprising an amino acid ester or a sphingolipid or derivative linked by a phosphorus oxide to a nucleotide or nucleoside. In certain embodiments, the disclosure contemplates pharmaceutical compositions comprising these compounds for uses in treating infectious diseases, viral infections, and cancer.

Enantiospecific formal total synthesis of iriomoteolide 3a

A formal total synthesis of the marine macrolide iriomoteolide 3a is described. Salient features of the synthesis include the elaboration of a β-keto phosphonate derived from d-(-)-tartaric acid and the extension of a chiral butyrolactone derived from L-g

2',3'-DIDEOXY-2'-α-FLUORO-2'-β-C-METHYLNUCLEOSIDES AND PRODRUGS THEREOF

The present invention provides 2',3'-dideoxy-2'-fluoro-α-2'-C- methylnucleosides, their prodrugs, and therapeutic use thereof as anti-HCV agents. The present invention also provides processes and intermediates for the preparation of the nucleosides disclosed herein.

Synthesis of the methylene bis-tetrahydropyran motif of (-)-exiguolide

A chiral-pool approach for the construction of methylene bis-tetrahydropyran subunit, C1-C16 fragment, of (-)-exiguolide is described. The synthesis was efficiently accomplished starting from l-glutamic acid and l-aspartic acid invol

Synthesis of 2'-C-α-methyl-2',3'-dideoxynucleosides

A general method for the synthesis of 2'-C-α-methyl-2',3'-dideoxynucleosides is presented. Stereofacial selectivity of the 2-C-methylation reaction of γ-lactone has been investigated, in which the presence of a bulky group at the 5-hydroxymethyl produced the α-isomer as a major product. During glycosylation, the α-methyl group directed the formation of nucleosides in favor of the β-isomer. This methodology is applied to the synthesis of some new pyrimidine and purine nucleosides.

Enantiopure DAVA-Derivatives-Part III. Synthesis of All 4 Stereoisomers of 2-Methyl-4-hydroxy-5-aminopentanoic Acid (2-Me-4-OH-DAVA)

A stereoselective synthesis of the 4 stereoisomers of 2-methyl-4-hydroxy-5-amino-pentanoic acid namely 2R,4S-9a, 2S,4S-9b, ent-9a and ent-9b is presented, starting from the known lactones S-1 and R-1, which are readily avalaible from L- and D-glutamic acid.Only ent-9b shows affinity for GABAB-receptors sites.

Lactols in Stereoselection 3. Highly anti-Cram Selective 1,2-Asymmetric Induction

Nucleophilic addition of MeTi(O-iPr)3 to α-chiral lactols proceeds in highly diastereoselective manner.The sense of the diastereofacial selection is anti-Cram-type, which provides a new and useful method for 1,2-asymmetric induction.